Literature DB >> 11330560

Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis.

J Malyszko1, J S Malyszko, M Mysliwiec.   

Abstract

OBJECTIVE: Disturbances in hemostasis are common findings in uremic patients. Both bleeding diathesis and thrombosis are observed. The purpose of this study was to assess whether renal replacement therapy in the form of hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD) affects coagulation and fibrinolysis in patients with end-stage renal failure.
DESIGN: Comparison of hemostatic measures in patients on CAPD, HD, and matched healthy controls.
SETTING: Department of Nephrology and Internal Medicine, Bialystok University School of Medicine. PATIENTS AND METHODS: Twenty-four HD patients and 23 CAPD patients were evaluated with respect to platelet aggregation, hemostatic parameters, serum lipids, lipoprotein(a), and cytokines [tumor necrosis factor alpha (TNFalpha) and interleukin-1 (IL-1)].
INTERVENTIONS: Four exchanges of CAPD per day, using 2.0 L dialysate over a period of 25 +/- 31 months; or 4-5 hours of HD 3 times per week for a period of 31 +/- 22 months.
RESULTS: Platelet aggregation in whole blood and platelet-rich plasma was significantly impaired in both groups of dialyzed patients compared to healthy volunteers. Markers of endothelial cell injury (thrombomodulin and von Willebrand factor) were significantly higher in HD and CAPD patients compared to the control group. A similar pattern of changes was observed for lipoprotein(a), fibrinogen, tissue factor pathway activity, and factor VII activity. Activity of factor X was significantly enhanced in CAPD compared to HD patients and controls. Euglobulin clot lysis time was significantly prolonged in HD and CAPD patients over controls, being more prolonged in CAPD patients. Markers of ongoing coagulation (thrombin-antithrombin complexes and prothrombin fragments 1+2) were higher in uremic patients, significantly higher in CAPD than in HD. A marker of ongoing fibrinolysis (plasmin-antiplasmin complexes) was higher in uremic patients but was lower in CAPD than in HD patients. Concentrations of TNFalpha and IL-1 were higher in HD than in CAPD patients.
CONCLUSION: Patients on CAPD showed evidence of a higher degree of hypercoagulation than HD patients.Thus, hemostatic abnormalities in end-stage renal failure may be affected to some extent by the choice of renal replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330560

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  8 in total

1.  Tissue factor pathway inhibitor in paediatric patients with nephrotic syndrome.

Authors:  Farida Ahmed Farid; Ahmed Abdullah Mohammed; Hanaa Mohammed Afifi; Rania Saleh Beltagi
Journal:  SAJCH       Date:  2011-12

2.  The uremic solute-AHR-tissue factor axis in vascular cells, mouse models and thrombosis in chronic kidney disease patients.

Authors:  Nigel Mackman; Jonathan H Erlich
Journal:  Ann Transl Med       Date:  2018-06

3.  Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.

Authors:  Zhong-Sen Qu; Qing-De Zhang; Liang Li
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.

Authors:  Danyelle R A Rios; Maria G Carvalho; Roberta C Figueiredo; Cláudia N Ferreira; Valério L Rodrigues; Regina A Souza; Ana C Simões e Silva; Ana Paula Fernandes; Karina B Gomes; Luci M S Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

5.  Protein Z and natural anticoagulants in children on peritoneal dialysis and hemodialysis.

Authors:  Kenan Bek; Ozan Ozkaya; Tunç Fişgin; Yüksel Aliyazicioğlu; M Sükrü Paksu; Tolga Ozgen; Davut Albayrak; Kemal Baysal
Journal:  Pediatr Nephrol       Date:  2006-11-24       Impact factor: 3.714

6.  Plasma von Willebrand Factor and a Disintegrin and Metalloproteinase with Eight Thrombospondin-type 1 Motif Levels in Hemodialysis Patients: Relation to Vascular Access Thrombosis.

Authors:  Khaled M A Elzorkany; Belal A M Montaser; Sally M El-Hefnawy
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

7.  Elevation of Platelet and Monocyte Activity Markers of Atherosclerosis in Haemodialysis Patients Compared to Peritoneal Dialysis Patients.

Authors:  Ksenija Stach; Susanne Karb; Ibrahim Akin; Martin Borggrefe; Bernhard Krämer; Thorsten Kälsch; Anna-Isabelle Kälsch
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

Review 8.  Thrombolome and Its Emerging Role in Chronic Kidney Diseases.

Authors:  Justyna Fryc; Beata Naumnik
Journal:  Toxins (Basel)       Date:  2021-03-18       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.